Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion

Summary

This is a Phase II, single arm, open label clinical trial. 60 RVO patients (including 30 BRVO and 30 CRVO, respectively) are enrolled in the study. The study included a fixed treatment period (3 months) and a PRN period (6 months). In the fixed treatment period patients will receive 3 consecutive monthly intravitreal of 0.5 mg Conbercept. In the PRN period, patients are monthly visited and retreatment will be needed according to the retreatment criteria pre-specified.

Timeline

Start

2012-05

Primary completion

2013-11

Completion

2014-03

Drugs

Indications